Nirsevimab: A Lab-Created Antibody for RSV Protection
Nirsevimab is not a vaccine but a lab-created monoclonal antibody that offers immediate protection by mimicking the immune response, rather than prompting the body to produce antibodies itself. This groundbreaking discovery could revolutionize the way we prevent severe respiratory syncytial virus (RSV) infections, particularly in infants.
Study Highlights
A research published in The Lancet Child and Adolescent Health journal found that injecting infants with nirsevimab reduces the risk of RSV-related hospitalizations by 83% and intensive care admissions by 81%. This could significantly address the health and economic burden of RSV in high-risk periods following birth.
Real-World Effectiveness
Nirsevimab was approved by regulatory agencies, including the US Food and Drug Administration and European Medicines Agency, after demonstrating safety and effectiveness in clinical trials. The study analyzed 27 previously published studies conducted during the RSV seasons of 2023-2024 across five countries: France, Italy, Luxembourg, Spain, and the US. The researchers focused on infants aged under 12 months.
Key Findings
-
Pooled Real-World Effectiveness:
- 83% against hospitalization
- 81% against intensive care admission
- 75% against lower respiratory tract infections
- Age-Dependent Effectiveness:
- More effective among infants aged over three months compared to those under three months.
Monoclonal vs. Vaccine
Nirsevimab is not a vaccine but a lab-created monoclonal antibody. Unlike vaccines, which empower the body’s immune system to produce antibodies, monoclonal antibodies mimic the natural immune response. This means nirsevimab offers immediate protection without the need for the body to produce its own antibodies.
Potential Impact
The findings suggest that the benefits of nirsevimab seen in clinical trials could be translated into real-world settings, potentially reducing the burden of RSV disease among infants and the use of healthcare resources.
Conclusion
Nirsevimab represents a significant advancement in RSV prevention, offering a new and effective tool for protecting infants against this common but serious respiratory infection. As more studies and real-world applications are conducted, the potential benefits of nirsevimab could be even more profound.
Reference : https://www.thehindu.com/sci-tech/health/study-finds-lab-created-antibody-effective-in-preventing-severe-respiratory-illness-in-infants/article69529822.ece
